{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '3', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'DOCUMENT HISTORY', 'Document', 'Date of Issue', 'Overall Rationale', 'Amendment 06', '15-SEP-2021', 'Data from an interim safety and futility eDMC for LEAP-007 (data cutoff:', '19-MAY-2021) indicated the study met the prespecified nonbinding', 'futility criteria for OS for the combination of lenvatinib plus', 'pembrolizumab compared with placebo plus pembrolizumab and the', 'benefit-risk assessment was not considered positive to continue the study.', 'This futility analysis was requested at a previous eDMC meeting and', 'conducted as described in the sSAP. Based upon these data, MSD', 'implemented this amendment to unblind the study and remove lenvatinib', 'and matching placebo from the study. In addition, the Second-course', 'Treatment Phase was discontinued and collection of ePRO data stopped.', 'The study will remain open to allow ongoing participants to continue', 'treatment with open-label pembrolizumab monotherapy up to a maximum', 'of 35 administrations.', 'Amendment 05', '02-MAR-2021', 'To update the assumptions and timing of the analyses in the SAP, allow', 'sufficient duration of follow-up, and to remove the initial alpha of ORR', 'and reallocate to primary endpoints of PFS and OS', 'Amendment 04 - China-specific', '11-FEB-2020', 'Extension of the enrollment period beyond the global study to achieve', 'required exposure and number of events to investigate efficacy and safety', 'in Chinese 1L NSCLC participants', 'Amendment 03', '16-DEC-2019', 'Alignment with Lenvatinib and Pembrolizumab (LEAP) program protocol', 'standards and Health Authority request', 'Amendment 02', '27-JUN-2019', 'Alignment with Lenvatinib and Pembrolizumab (LEAP) program protocol', 'standards', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '4', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Document', 'Date of Issue', 'Overall Rationale', 'Amendment 01', '17-JAN-2019', 'Alignment with Lenvatinib and Pembrolizumab (LEAP) program protocol', 'standards', 'Original Protocol', '09-NOV-2018', 'N/A', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '5', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'PROTOCOL AMENDMENT SUMMARY OF CHANGES', 'Amendment: 06', 'Overall Rationale for the Amendments:', 'Data from an interim safety and futility eDMC for LEAP-007 (data cutoff: 19-MAY-2021) indicated the study met the prespecified', 'nonbinding futility criteria for OS for the combination of lenvatinib plus pembrolizumab compared with placebo plus pembrolizumab', 'and the benefit-risk assessment was not considered positive to continue the study. This futility analysis was requested at a previous', 'eDMC', 'meeting', 'and conducted as described in the sSAP. Based upon these data, MSD implemented this amendment to unblind the', 'study and remove lenvatinib and matching placebo from the study. In addition, the Second-course Treatment Phase was discontinued', 'and collection of ePRO data stopped. The study will remain open to allow ongoing participants to continue treatment with open-label', 'pembrolizumab monotherapy up to a maximum of 35 administrations.', 'Summary of Changes Table:', 'Section # and Name', 'Description of Change', 'Brief Rationale', '1.1 Synopsis', 'Revised text and added notes to clarify the', 'In accordance with the overall rationale for the', '1.2 Schema', 'removal of lenvatinib and placebo', 'amendment, administration of lenvatinib and matching', 'treatments, Second-course Phase,', 'placebo, the Second-course Treatment Phase, and the', 'collection of ePRO, and collection of', 'collection of ePRO data and posttreatment imaging have', 'posttreatment imaging. Extension Study in', 'been removed from the study.', 'China was also stopped', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}